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Vascular endothelial growth factor (VEGF)–targeted antiangiogenic therapy significantly inhibits the growthof clear cell
renal cell carcinoma (RCC). Eventually, therapy resistance develops in even the most responsive cases, but the
mechanisms of resistance remain unclear. Herein, we developed two tumor models derived from an RCC cell line by
conditioning the parental cells to two different stresses caused by VEGF-targeted therapy (sunitinib exposure and
hypoxia) to investigate the mechanism of resistance to such therapy in RCC. Sunitinib-conditioned Caki-1 cells in vitro
did not show resistance to sunitinib compared with parental cells, but when tested in vivo, these cells appeared to be
highly resistant to sunitinib treatment. Hypoxia-conditioned Caki-1 cells are more resistant to hypoxia and have
increased vascularity due to the upregulation of VEGF production; however, they did not develop sunitinib resistance
either in vitro or in vivo. Human endothelial cells were more proliferative and showed increased tube formation in
conditioned media from sunitinib-conditioned Caki-1 cells compared with parental cells. Gene expression profiling
using RNA microarrays revealed that several genes related to tissue development and remodeling, including the
development andmigration of endothelial cells, were upregulated in sunitinib-conditioned Caki-1 cells compared with
parental and hypoxia-conditioned cells. These findings suggest that evasive resistance to VEGF-targeted therapy is
acquired by activation of VEGF-independent angiogenesis pathways induced through interactionswith VEGF-targeted
drugs, but not by hypoxia. These results emphasize that increased inhibition of tumor angiogenesis is required to delay
the development of resistance to antiangiogenic therapy and maintain the therapeutic response in RCC.
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Angiogenesis is an essential process for the growth and spread of
tumors, and blocking tumor angiogenesis has been used as a
therapeutic strategy against many types of cancer [1]. Because vascular
endothelial growth factor (VEGF) plays a central role in tumor
angiogenesis, therapeutic approaches have focused on inhibition of
the VEGF pathway [2]. Renal cell carcinoma (RCC) is generally
resistant to conventional chemo- and radiotherapy and is a highly
vascular tumor. VEGF is highly upregulated in RCC cells, likely
because of mutations in the Von Hippel-Lindau gene, which induces
degradation of hypoxia-inducible factor-1α through ubiquitination
and is mutated in 75% of sporadic clear cell type RCCs [3]. VEGF is
the key element in the pathogenesis of RCC, and VEGF receptor
tyrosine kinase inhibitors have been successfully applied to treat RCCand have shown clinical benefits [4]. One multityrosine kinase
inhibitor (TKI) that targets the VEGF and platelet derived growth
806 Cellular Adaptation to VEGF-Targeted Therapy Han et al. Neoplasia Vol. 17, No. 11, 2015factor (PDGF) receptor tyrosine kinases, sunitinib, has improved the
outcomes of RCC patients compared with other therapies, such as
cytokine therapy, and is currently considered a first-line option in patients
with advanced RCC [5].
Unfortunately, durable and complete responses to TKIs are rare,
and treatment has typically been associated with the development of
resistance after short-term disease stabilization. There are several
hypotheses regarding the development of evasive resistance to
antiangiogenic therapy, but the exact mechanisms remain unknown.
Because TKIs act on the endothelium’s angiogenic cascade, therapy
resistance cannot be explained simply by mutations within the
important mediators in the angiogenic cascade [5]. Antiangiogenic
therapy induces several stresses in cancer cells either directly or
indirectly by inhibiting tumor endothelial cells. One of the initial
responses to antiangiogenic therapies is the decrease in vessel number
and function and the consequently increased intratumor hypoxia.
Also, single-agent antiangiogenic therapy-induced tumor hypoxia
may increase the expression of other proangiogenic factors, causing
resistance to the initial drug [6]. Evidence for the existence of evasive
resistance originating from alternative proangiogenic signaling was
revealed during preclinical trials in a genetically engineered mouse
model of pancreatic neuroendocrine (islet cell) cancer, Rip1-Tag2
[7,8]. In this study, the resistant tumors expressed higher levels of the
mRNAs for the proangiogenic factors fibroblast growth factor (FGF)
1 and 2, ephrin A1 and A2, and angiopoietin 1, and the addition of
FGF inhibitor suppressed revascularization and tumor growth. These
studies suggested that antiangiogenic therapy-induced hypoxic stress
may induce overexpression of different proangiogenic factors, resulting
in resistance to VEGF-targeted therapy.
Although antiangiogenic therapy targets genetically stable endothelial
cells in the tumor vasculature, genetic alterations that decrease the
vascular dependence of tumor cells can influence the therapeutic response
of tumors [9]. It has been reported that the hypoxia generated by
angiogenesis inhibition triggers pathways resulting inmore aggressive and
metastatic tumors. In glioblastoma multiforme, cancer cells can migrate
as diffuse colonies into the surrounding brain without initiating
angiogenesis [8,10]. In addition, cancer cells can adapt to a hypoxic
environment when tumor angiogenesis is inhibited by selection of clones
that are p53 negative, and therefore become hypoxia resistant [9]. These
studies proposed variousmethods by which cancer cells can growwithout
the recruitment of new blood vessels, and expansion of hypoxia-resistant
clones selected by chronic hypoxic stress through angiogenesis inhibition
could be a cause of resistance to antiangiogenic therapy.
In this study, we show that chronic hypoxic stress induces
overproduction of VEGF and hypoxia resistance in RCC cells, but
tumor cells adapted to hypoxia remain dependent onVEGF, and hypoxic
stress does not induce in vivo resistance to VEGF-targeted antiangiogenic
therapy in RCC xenografts. In contrast, we show that VEGF-targeted
antiangiogenic drugs directly affect RCC cells and induce tumor cell
production of several VEGF-independent proangiogenic factors, thereby
inducing evasive resistance in RCC xenografts.
Materials and Methods
Reagents
Sunitinib was used as a VEGF-targeted tyrosine kinase inhibitor.
Free-base sunitinib and sunitinib malate were purchased from LC
Laboratories. Mass spectrometry was used to ensure the quality of
sunitinib compared with its pharmaceutical-grade counterpart (Pfizer,NY). Free-base sunitinib was preserved as aliquots at a concentration of
10mM inDMSO (Sigma) for in vitro experiments, and sunitinibmalate
was mixed with citrate-buffered solution (pH 3.5) for in vivo studies.
Cell Culture
Human clear cell type RCC cell lines Caki-1 and Caki-2 were
purchased from the American Type Culture Collection. Caki-1 and
Caki-2 were maintained with McCoy’s 5A medium (Invitrogen)
containing 10% fetal bovine serum (FBS). The other human RCC
cell lines, UMRC-3 and UMRC-6, were kindly gifted by Dr. P. Black
(Vancouver Prostate Centre, UBC). UMRC-3 and UMRC-6 were
maintained in MEM medium (Invitrogen) containing 10% FBS and
L-glutamine. The human renal proximal tubular epithelial cell line
HK-2 was kindly provided by Dr. C. Du (Vancouver Prostate Centre,
UBC). HK-2 cells were cultured in DMEM/Ham’s F12 (Invitrogen)
supplemented with 10% FBS and glutamine. Immortalized human
umbilical vascular endothelial cells (HUVECs) were obtained from
Dr. C. Du and maintained with EBM-2 medium (Lonza) containing
EGM-2 SingleQuots (Lonza). All cells were cultured at 37°C in a humid
atmosphere with 5% CO2. Mycoplasma contamination was tested. For
all in vitro studies, cell lines were passaged for a maximum of 2 months.
Establishment of Sunitinib-Conditioned Tumor Cells
Caki-1 cells were plated in 15-cm plates with McCoy’s 5A medium
with 10% FBS, grown to 50% confluence, and incubated overnight for
attachment. Cells were then exposed to sunitinib by replacing media
with fresh sunitinib-containingmedia. The sunitinib concentration and
exposure time were adjusted depending on the tolerance of the cells.
Cells were exposed to sunitinib for 3 to 5 days, and media were replaced
with freshmedia without sunitinib for 24 to 48 hours. Cells that showed
proliferation at a specific sunitinib concentration were replated and
exposed to a higher concentration (b25% higher than the previous
concentration). If the increased concentration was not tolerated, the
cells were maintained in media with an identical or lower sunitinib
concentration. The sunitinib on-off exposure cycle was maintained
until the cells could proliferate in the presence of the target
concentration (approximately 14-20 cycles). The final tolerated
concentration of sunitinib was 15 μmol/l. Cells at all steps were frozen
after use. Mycoplasma contamination was evaluated every five cycles.
Establishment of Hypoxia-Conditioned Tumor Cells
Caki-1 cells were plated onto a 15-cm plate with McCoy’s 5A
medium with 10% FBS, grown to 50% confluence, and incubated
overnight for attachment. Cells were then exposed to hypoxia (1%
oxygen) until they became confluent. Cells were maintained in the
hypoxia chamber in same manner, excluding passaging. When the
cells became confluent, they were replated in normoxic conditions
and incubated in a normoxic tissue culture incubator for 24 hours.
Hypoxic conditions (1% oxygen) were induced using a hypoxia
chamber (Coy Corporation). During each hypoxic exposure cycle,
development of resistance to hypoxia was tested by examining the
growth of hypoxia-conditioned cells and parental cells under hypoxic
conditions. For all in vitro experiments, cells were maintained under
hypoxic conditions before use. For in vivo studies, cells were maintained
under hypoxic conditions until injection.
Cell Viability Assay
Cells were seeded onto 48-well plates at a density of 1.5 × 104 per
well in media with 10% FBS and allowed to attach for 24 hours.
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normoxic or hypoxic (1% O2) conditions. After 48 hours of
treatment, cells were fixed with 10% glutaraldehyde and stained with
0.5% crystal violet solution. Cells were then washed with water and
dried. Stained crystal violets were resolved in Sorensen’s solution, and
absorbance was measured at 520 nm using a spectrophotometer. All
experiments were performed in triplicate and repeated a minimum of
three times.
Anchorage-Independent Cell Growth Assay
Culture plates (48 wells) were coated with 0.5 ml of the bottom
agar mixture (1× RPMI, 10% FBS, and 0.6% agar) and solidified at
4°C. Cells (1.5 × 103) were trypsinized and resuspended in 0.5 ml of
top agar mixture (1× RPMI, 10% FBS, and 0.3% agar) containing
various doses of sunitinib. The top agar mixtures containing cells were
added to the prepared bottom agar mixture. Plates were incubated at
37°C for 14 days, and medium was added once per week. Colonies
were stained overnight at 37°C with 0.05% crystal violet in ethanol,
and the colonies were visualized at 50× magnification; five different
fields were counted manually using Axiovision software, and the
average number of colonies per well was calculated. All experiments
were performed in triplicate and repeated three times.
Cell Cycle Analysis
At 30% to 40% confluency, cells were synchronized at G0/G1
phase by eliminating serum from the culture medium for 24 hours.
After release from the G1 block by substitution with fresh media
containing 10% FBS, cells were maintained for 24 hours. Cells were
fixed with 70% ethanol at −20°C overnight and then treated with 10
μg/ml of RNAase and stained with 100 μg/ml of propidium iodide
(PI). Cell cycle phase was determined by flow cytometry. All
experiments were performed in triplicate and repeated three times.
Quantitative Reverse Transcription Polymerase Chain
Reaction (PCR)
RNA was extracted from cell lines using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. RNA was
quantified by the ratio of absorbance at 260/280 nm. First-strand
cDNA was synthesized from 2 μg of RNA by reverse transcriptase
(Invitrogen) with a random hexamer primer. Primers for PCR were as
follows: VEGF-A, basic FGF, PlGF, IL-8, MMP-2, TSP-1, and 18S
rRNA. All experiments were performed in triplicate and repeated a
minimum of three times.
Tumor Xenografts
All animal studies were performed in accordance to the guidelines
of the Canadian Council on Animal Care with institutional
certifications (University of British Columbia). Parental Caki-1 cells
(Caki-1-WT), hypoxia-conditioned Caki-1 cells (Caki-1-HC), and
sunitinib-conditioned Caki-1 cells (Caki-1-SC) (5 × 106 cells) were
injected subcutaneously (s.c.) in the flank region of 8- to 10-week-old
nude mice. When tumors reached a volume of 100 to 200 mm3, mice
were randomized and divided into two groups (sunitinib versus
vehicle treatment). Each treatment group consisted of eight mice.
Sunitinib malate was suspended in citrate-buffered solution (pH 3.5).
Tumor-bearing mice were orally administered sunitinib malate
(40 mg/kg) or vehicle (citrate-buffered solution) once daily.
Tumor volume was calculated using the equation tumor volume (mm3) =
length × width × height × 0.5 and measured every 3 days using calipers.Tumors were harvested at various time points including the start of
treatment and during treatment, according to responses. Tumors were
fixed in formaldehyde, paraffin embedded for immunohistochemical
staining, and frozen in liquid nitrogen for protein and mRNA analyses.
For hypoxia staining, pomonidazole was injected intravenously 30
minutes before euthanization. Mice were anesthetized, and tumor
tissues were extracted immediately so that the tissue hypoxia status was
not affected. All animals at the completion of the study were euthanized
by inhalation of CO2 according to the animal ethics protocol.
Tumor Reimplantation
Caki-1-WT and Caki-1-SC xenografts were used for reimplanta-
tion. Xenograft tumors, treated with either sunitinib or vehicle, were
obtained before sacrifice at the end of the previous experiment.
Immediately after sacrifice, tumors were excised and cut into 3 × 3 ×
3–mm cubic pieces and implanted s.c. into 6- to 8-week-old female
nude mice. When tumors reached 200 to 300 mm3, they were
randomly divided into two groups followed by treatment with
sunitinib or vehicle.
In vivo Angiogenesis Assay
Caki-1-WT and Caki-1-SC cells in exponential growth were
harvested, and 1 × 106 cells in 300 μl of Matrigel were implanted s.c.
into the flanks of 6- to 8-week-old female nude mice. Ten days
postimplantation, mice were divided into two groups; one group was
treated with sunitinib (40 mg/kg per day) and the other with vehicle.
After 5 days of treatment, all mice were sacrificed, and the implanted
plugs were excised and embedded in Tissue-Tek O.C.T. compound
(Sakura Finetek USA, Torrance, CA). After being frozen at −80°C for
1 hour, 5-μm sections were cut from the embedded tissues using a
CM1850 cryostat (Leica Microsystems, Richmond Hill, ON, Canada)
and applied to glass slides. Immunofluorescence staining was performed
using a rat anti-mouse CD31 antibody.
Tube Formation Assay
Low-passage HUVECs were cultured in M199 media with 20%
FBS and starved for 4 hours before the tube formation assay.
HUVECs were mixed with media containing 1% FBS and then
seeded on Matrigel-coated 24-well plates at a density of 104 cells per
well. VEGF and various doses of sunitinib were added to the media
for VEGF-dependent tube formation assays. Conditioned media
from tumor cells were used for the tube formation assay as a validation
study of the in vivo angiogenesis effect. Caki-1 cells and
sunitinib-conditioned Caki-1 cells were cultured in complete
media. Media were replaced by media containing 1% FBS at 50%
confluency. After 24 hours, the conditioned media were filtered and
directly added to HUVECs for the tube formation assay. Tube
formation was evaluated using a microscope, and photographs were
taken 3 to 18 hours after seeding. The area covered by the tube
network was determined with an optical imaging technique. Images
of the tubes were scanned into Adobe Photoshop and quantified using
Image J software.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed,
paraffin-embedded 4-μm tumor sections using the appropriate
primary antibody (mouse anti-CD31 and anti-pimonidazole anti-
bodies) and the Ventana autostainer Discover XT (Ventana Medical
Systems) using an enzyme-labeled biotin streptavidin system and
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intensity comparisons were made at 200× magnification and scored
independently by two histopathologists (Dr. L.F. and Dr. K.H.).
mRNA Microarray
Total RNA from the parental Caki-1 cells, sunitinib-conditioned
Caki-1 cells, and hypoxia-conditioned Caki-1 cells were obtained
using the TRIzol method. Three independent RNA samples were
obtained from the cells to minimize experimental variation.
Microarrays of 21,000 (70-mer) human oligonucleotides representing
21,000 genes (Operon Technologies) printed in duplicate in 3× SSC
onto aminosilane-coated slides (ERIE C28) were supplied by the
Array Facility of The Prostate Center at Vancouver General Hospital.
Arrays were hybridized with 3DNA DNA Dendrimer Probes
generated from 10 μg of total RNA according to the manufacturer’s
protocol (Genisphere). Briefly, reverse transcription incorporated a
specific sequence present on the 5′ end of the reverse transcription
primer supplied with the kit. The complementary DNA was
hybridized to the array overnight at 42°C. After stringent washes,
the fluorescent 3DNA reagent, which included a “capture sequence”
complementary to the sequence at the 5′ end of the reverse
transcription primer, was hybridized to the complementary DNA
(47°C for 2-3 hours). After washing, the arrays were immediately
scanned on a ScanArrayExpress Microarray Scanner (PerkinElmer).
Signal quality and quantity were assessed using Imagene 5.6
(BioDiscovery). Data from Imagene were analyzed in GeneSpring
7.2 (Silicon Genetics) for profiling of changes in gene expression.
Analyses performed in GeneSpring included background correction,
LOWESS normalization, and hierarchical clustering using standard
correlation. Differentially expressed genes were identified by
two-sample t tests, and P values were adjusted for multiple
comparisons using the false-discovery rate method of Benjamini
and Hochberg. The Ingenuity Pathway Analysis (Mountain View,
CA) was used to examine functional and network associations
between differentially expressed genes. Significances for biological
functions were compared with the whole Ingenuity Pathway
Knowledge Base as a reference set.
Results
Effect of Sunitinib on Angiogenesis in Human RCC Cells
We examined the direct effect of the VEGF-targeted tyrosine
kinase inhibitor, sunitinib, on cell proliferation in both RCC and
endothelial cells using anchorage-dependent and -independent cell
proliferation assays. Crystal violet assays after sunitinib treatment
demonstrated that tumor cell growth was inhibited by sunitinib in all
RCC cells (Caki-1, Caki-2, UMRC-3, and UMRC-6) and normal
renal epithelial cells (HK-2) in a dose-dependent manner (Figure 1A).
The IC50 was 4 to 8 μM for RCC cells and 15 μM for normal renal
cells. Although sunitinib suppressed tumor cell proliferation at higher
doses, these are not considered pharmacologically relevant doses (b1
μM). To further evaluate the effect of sunitinib on tumor growth, we
performed anchorage-independent colony formation assays using
Caki-1 and Caki-2 cells. These assays confirmed that tumor cell
growth was not inhibited by sunitinib at pharmacologically relevant
doses (Figure 1B). We also examined the effect of sunitinib on cell
cycle progression in RCC using FACS cytometry with PI staining.
Cell cycle analysis showed that sunitinib induced G0/G1 phase arrest
at high doses but had no effect on cell cycle progression at low doses(Figure 1C). In contrast, cell growth assays with HUVECs revealed
that proliferation was effectively inhibited by sunitinib at low doses
(IC50) (Figure 1D). We next performed a tube formation assay to
corroborate this finding. Tube formation was also inhibited by low
doses of sunitinib (b1 μM), confirming that sunitinib suppressed
endothelial cell growth and angiogenesis but not RCC cell proliferation.
Chronic Hypoxia Increases the Hypoxia Resistance of
RCC Cells
To evaluate whether chronic hypoxic stress increased the resistance
to hypoxia of RCC cells, Caki-1 cells were chronically exposed to 1%
O2 hypoxic conditions using a hypoxia culture chamber. Cell growth
assays showed that hypoxia reduced tumor cell growth when the cells
were initially exposed to hypoxia; however, after several passages, the
growth rate was restored (Figure 2A). The resistance increased
depending on the hypoxic exposure time, and cell proliferation was
increased in normoxia compared with parental cells, but there was no
increase in resistance after 15 passages under hypoxic conditions.
Next, we tested hypoxia-conditioned cells with sunitinib to evaluate
the effects of chronic hypoxia on sunitinib response. Cell growth
assays using hypoxia-conditioned Caki-1 cells (Caki-1-HC) showed
the same pattern as did those using parental Caki-1 cells
(Caki-1-WT), suggesting that hypoxia does not affect the response
to sunitinib (Figure 2B).
Chronic Exposure to Sunitinib Does Not Induce In Vitro
Resistance to Sunitinib in RCC Cells
To evaluate whether chronic adaptation to sunitinib induces
resistance to sunitinib in RCC, Caki-1 cells were chronically exposed
to sunitinib. Cells were initially exposed to low doses of sunitinib,
which were then increased sequentially. Caki-1 cells stably adapted to
10 μM sunitinib (Caki-1-SC). The cell growth assay revealed that
sunitinib-conditioned Caki-1 cells (Caki-1-SC) were more resistant to
sunitinib, and the IC50 increased from 4 to 8 μM to 10 to 15 μM
(Figure 2B). However, there was no significant difference in sunitinib
sensitivity at pharmacologically relevant doses between Caki-1-WT
and Caki-1-SC cells. We next tested the hypoxia resistance of
Caki-SC cells to evaluate the effect of chronic sunitinib stress on
tolerance to hypoxia in renal carcinoma cells. Caki-1-SC cells were
more tolerant to hypoxic stress than were parental cells but less
tolerant than hypoxia-conditioned cells (Figure 2A).
Chronic Adaptation to Sunitinib or Hypoxia Changes
Expression Patterns of Proangiogenic Factors in RCC Cells
Changes in proangiogenic properties of RCC cells after exposure to
hypoxia or sunitinib were assessed using reverse transcription PCR.
VEGF mRNA expression levels were significantly increased in
Caki-1-SC cells and even higher in Caki-1-HC cells compared with
Caki-1-WT cells (Figure 3A). ELISA confirmed these differences in
VEGF expression (Figure 3B). We also examined the expression of
the proangiogenic factors FGF2 and IL-8, which may play a role in
the resistance to VEGF-targeted antiangiogenic therapy [7,11]. FGF2
expression was not significantly increased by chronic adaptation to
sunitinib or hypoxia (Figure 3C). IL-8 was increased only by chronic
adaptation to Caki-1-HC cells, but its expression remained relatively
low (Figure 3D). These results suggest that cellular adaptation to
hypoxia makes RCC cells more angiogenic, which is dependent on
overproduction of VEGF. We also examined the expression of other
proangiogenic factors including PlGF, angiopoietin, TGFβ1,
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differ significantly (data not shown).
Effects of Chronic Sunitinib and Hypoxia In Vivo
We investigated the effects of chronic adaptation to sunitinib and
hypoxia on sunitinib resistance in vivo using a subcutaneous xenograft
model with both Caki-1-WT and conditioned Caki-1 cells. Daily oral
sunitinib treatment inhibited tumor growth by up to 75% in
xenografts developed by parental cells (Figure 4A). The growth ofCaki-1-HC tumors was suppressed by sunitinib treatment, and their
growth was identical to that of Caki-1-WT tumors (Figure 4B). In
comparison, Caki-1-SC tumors were more resistant to sunitinib
treatment compared with Caki-1-WT tumors (Figure 4, C andD). To
confirm these findings, we reimplanted tumors into sunitinib-treated
naïve mice following treatment. The reimplanted xenografts from
Caki-1-WT tumors responded to sunitinib, whereas Caki-1-SC tumors
remained resistant to sunitinib (Figure S1). Therefore, resistant tumors
remain resistant to sunitinib even when placed in new environments.
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Neoplasia Vol. 17, No. 11, 2015 Cellular Adaptation to VEGF-Targeted Therapy Han et al. 811These data suggest that resistance to sunitinib is developed primarily
by tumor cells but not by tumor endothelial cells and that these changes
are persistent.
Effect of Chronic Suppression of VEGF in Tumor Cells on
Other Angiogenic Factors
Immunohistochemical staining for the expression of vascular
marker CD31 was performed on xenografts to assess the effect of
sunitinib on angiogenesis. Microvessel density was markedly reduced
in Caki-1-WT and Caki-1-HC xenografts. Conversely, similar to
vehicle-treated controls, Caki-1-SC tumors exhibited a microvessel
density that was relatively intact (Figure 5A). We also examined
hypoxia in tumor xenografts using immunohistochemical staining
with an antipimonidazole antibody. Consistent with the results
described above, pimonidazole expression was high in Caki-1-WT
and Caki-1-HC tumors treated with sunitinib but low in Cali-1-SC
tumors (Figure 5B). To investigate whether this difference originates
at the beginning of treatment or occurs at a later stage, xenografts
were retreated with sunitinib (40 mg/kg) for 5 days and harvested to
assess tumor vaculature using CD31 (Figure 5C). Taken together,Treatment Day
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To confirm these findings, we used in vivo Matrigel or tumor
xenograft models to assess the effect of sunitinib on different cell lines.
Microvessel density after 5 days of sunitinib treatment was highest in
the xenografts originating from sunitinib-conditioned cells compared
with parental cells and hypoxia-conditioned cells. Matrigel plug assays
in nude mice showed that immunofluorescent staining with CD31
revealed a remarkable disappearance of microvessels in the plugs
containing Caki-1-WT cells, whereas vessels were relatively intact in
the plugs containing Caki-1-SC cells as well as the xenografts
(Figure 6, A and B). To investigate the existence of alternative
endothelial cell growth factors escaping the angiogenic suppression of
sunitinib, conditioned media from Caki-1-SC and Caki-1-WT cells
were applied to HUVECs, which were then assessed for in vitro
angiogenesis following sunitinib treatment. Tube formation assays
also confirmed the findings from the Matrigel plug assay. HUVEC
tube formation was completely suppressed by sunitinib at 1.0 and
2.0 μM in conditioned media from the Caki-1-WT cells, whereasTreatment Day
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(Figure 6C). These data suggest that tumor cells are able to chronically
adapt to sunitinib treatment and continue angiogenesis even with
VEGF inhibition.
Effect of Sunitinib on VEGF-Independent
Angiogenic Pathways
To identify the factors responsible for sunitinib resistance, the
mRNA profiles of parental cells, sunitinib-conditioned cells, and
hypoxia-conditioned cells were compared using mRNA microarrays
(Table S1). RNA profiling revealed that some neuronal guiding and
angiogenic factors were highly expressed in Caki-1-SC cells but not in
Caki-1-WT or Caki-1-HC cells (Figure 7A). We found that neuronal
guidance factors, such as Reelin, were highly upregulated, as were
angiogenic factors Notch and BMP-6 in sunitinib-conditioned cells
compared with parental and hypoxia-conditioned cells (Figure 7, B
and C). Western blot analysis was performed to corroborate the
findings from the mRNA microarray (Figure 7D). Taken together,
these results suggest that chronic inhibition of VEGF signaling in
tumor cells increases the expression of different growth factors, which
may induce angiogenesis (Figure 7, E and F). These growth factors
can induce evasive resistance by compensating for the inhibition of
VEGF signaling in RCC cells.Discussion
During antiangiogenic therapy, antitumor effects are achieved
primarily by inducing hypoxia secondary to reducing tumorA
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Figure 5. Changes in tumor angiogenesis by cell conditioning with
vasculature in xenografts treated with sunitinib (40 mg/kg) or vehicle
pimonidazole by injection with pimonidazole 30 minutes before sacrmicrovessels, which, in turn, leads to apoptotic cell death or necrosis.
Anti-VEGF–induced hypoxic stress alters the expression patterns of
proangiogenic factors from tumor cells. Unfortunately, tumor cells
modify their angiogenic profiles to maintain adequate vasculature to
proliferate even during VEGF inhibition. Several proangiogenic
factors, such as FGF, ephrins, angiopoietin, and IL-8, are over-
expressed in resistant tumors treated with VEGF-targeted therapy,
and inhibition of these growth factors inhibits tumor growth [7,11].
However, the development of evasive resistance to antiangiogenic
therapy remains unclear. Interestingly, we have shown that simple
hypoxic stress was not sufficient to trigger resistance to antiangiogenic
therapy. In contrast, VEGF-targeted inhibition induced overexpres-
sion of several proangiogenic factors, which was not dependent on
VEGF. Thus, tumor cell overexpression of angiogenic growth factors
induced in vivo resistance to VEGF-targeted therapy in RCC cells.
Reduced reliance on vascular supply is believed to be one
mechanism of resistance to antiangiogenic therapy [10]. Hypoxic
stress induces several phenotypic changes in tumor cells. After
hypoxia, tumor cells become more angiogenic, proliferative, and
metastatic [6]. Hypoxic tumor cells induce several factors to stimulate
angiogenesis, of which the upregulation of HIF-1α plays a crucial
role. HIF-1α modulates cell cycle arrest, has pro- and antiapoptotic
effects, induces glycolysis, and stimulates angiogenesis through
upregulation of VEGF [12–14]. Tumor cells deficient in p53 display
a diminished rate of apoptosis under hypoxic conditions, which may
reduce their reliance on vascular supply and their responsiveness to
antiangiogenic therapy [10]. Tumor cells resistant to hypoxia surviveWT SC HC
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and increasing their movement toward oxygen. In a previous study,
p53-mutated human colorectal cancer cells were less responsive to
antiangiogenic combination therapy (DC101/Vbl), and p53-induced
hypoxia resistance was thought to play a key role in antiangiogenic
therapy resistance. However, p53 mutations induced overexpression
of proangiogenic factors such as FGF, IL-8, IGF, and VEGF andcould induce hypoxia resistance in tumor cells [15–17]. Therefore,
resistance to antiangiogenic therapy after a p53 mutation could be
derived from overexpression of several proangiogenic factors, as well
as a reduced reliance on oxygen. Our data showed that hypoxia
reduced the reliance of tumor cells on oxygen, and chronic exposure
to hypoxia increased the general angiogenic potential of tumors.
However, VEGF was mostly overexpressed under only hypoxia-induced
814 Cellular Adaptation to VEGF-Targeted Therapy Han et al. Neoplasia Vol. 17, No. 11, 2015stress conditions, suggesting that tumor cells remain dependent on
VEGF for their angiogenesis. Thus, in vivo resistance in RCC cells was
not acquired by simple exposure to hypoxia.
The direct effects of VEGF-targeted therapy on tumor cells have been
investigated but remain unclear. Recent studies reported that sunitinib
induced cell apoptosis and growth arrest in RCC and medulloblastoma
tumor cells by inhibiting signal transducer and activator of transcription
3 [18,19], whereas another study reported no direct cytotoxic effects of
sunitinib against tumor cells. Sunitinib showed no significant effects on
tumor cell proliferation or apoptosis at pharmacologically relevant doses
[20]. However, VEGFR inhibition by sunitinib may affect tumor cells,
and chronic inhibition of VEGFR signals on tumor cells could induce
molecular and phenotypic changes, even though pharmacologicallyD
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different stimulators over time [21]. Recently, FGF and IL-8 were
proposed to be proangiogenic by bypassing VEGF signaling
inhibition through inducing the growth of vascular endothelial cells
[7,11]. In our study, there was no increase in FGF expression in the
resistant RCC after exposure to hypoxia or sunitinib. Recently, IL-8
was also reported to be a candidate proangiogenic factor that plays a
role in sunitinib resistance. Specific inhibition of these factors also
suppressed tumor growth in resistant tumors, but the effects were
modest and temporary. Tumor cells adapted to hypoxia exhibited a
moderate increase in IL-8 expression but no in vivo resistance to
antiangiogenic therapy in our study. Instead, we found prominent
increases in several growth factors, which may induce endothelial cell
growth and angiogenesis in resistant tumor cells. The most
overexpressed factors in our resistance model were Reelin and Netrin,
which are known to regulate axon guidance [22,23]. However, recentstudies revealed that Reelin and Netrin also play a role in lymphatic
and vascular formation [24,25]. Neuronal growth factors have been
suggested to be related to angiogenesis because their sprouting and
growth patterns are similar to the process of angiogenesis. Ephrins are
important factors in embryonic patterning and neuronal targeting and
function as a neuronal guidance cue. They are also known to play a
critical role in vascular development during embryogenesis [26].
Furthermore, ephrin-B2 regulates VEGFR2 function in develop-
mental and tumor angiogenesis [27]. Eph/ephrin-dependent
tumor neovascularization is mediated by the interplay of Eph
receptors/ephrin ligands expressed by tumor cells and endothelial cells
[26]. Recent studies demonstrated that the neuronal guidance cues by
ephrin B proteins are essential for Reelin signaling during the
development of laminated structures in the brain [28], suggesting
that Reelin may play a role in tumor angiogenesis. In addition, resistant
cells showed increased Jagged2 expression. Activation of the Notch
816 Cellular Adaptation to VEGF-Targeted Therapy Han et al. Neoplasia Vol. 17, No. 11, 2015system leads to a more mature vasculature, which, in turn, increases
tumor perfusion [6]. Tumors intrinsically resistant to anti-VEGF agents
appear to be sensitive to inhibition of Notch signaling [29].
Conclusions
Our data suggest that tumor angiogenesis is not fixed to VEGF
signaling and that there is redundancy in the angiogenic potential of
tumor cells. Tumor cells recognize VEGFR inhibitory signals and
change their angiogenic factor profiles according to the inhibitory
signals of certain proangiogenic factors. Resistance to VEGF-targeted
therapy is induced not by a single but by several proangiogenic factors
independent of VEGF. Although novel VEGF-targeted therapies,
including axitinib, pazopanib, and tivozanib, have been developed
recently and show improved clinical outcomes, broader inhibition
of several proangiogenic factors is required to prevent resistance to
antiangiogenic therapy.
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